Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer

Carmen Gomez-Fernandez, Yahya Daneshbod, Mehdi Nassiri, Clara Milikowski, Consuelo Alvarez, Mehrdad Nadji

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


We evaluated the estrogen receptor (ER) phenotype of recurrent and/or metastatic breast cancers and compared it with the ER status of the primary tumor in 278 cases. All patients had undergone surgical excision of the primary tumor, followed by observation only or treatment modalities that included radiation and/or chemotherapy or hormonal therapy. The immunohistochemical expression of ER was evaluated by using monoclonal antibody ER-1D5 and heat-induced antigen retrieval. At diagnosis, 165 patients had locoregional disease and 7 had distant metastases. Local recurrences and/or distant metastases occurred from 2 months to 21 years after the diagnosis of the primary tumor. Overall, 159 primary tumors (57.2%) were positive for ER. In 269 cases (96.8%), the ER status of the primary and metastatic tumors was the same. In 9 patients with ER+ primary tumors, the metastases were ER-. There were no ER- primary tumors with ER+ metastases. The time to distant metastasis was significantly longer for ER+ tumors. The immunohistochemically determined ER phenotype of primary breast cancers remains stable in most recurrent and metastatic disease.

Original languageEnglish (US)
Pages (from-to)879-882
Number of pages4
JournalAmerican journal of clinical pathology
Issue number6
StatePublished - Dec 2008


  • Breast cancer
  • Estrogen receptor
  • Immunohistochemistry
  • Metastatic breast carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer'. Together they form a unique fingerprint.

Cite this